Φορτώνει......
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome
Reduction of APL antibodies by immunoadsorption may be a lifesaving therapy for the management of DAH with high titer of APL antibodies. Autologous HSCT may be a valid treatment option in patients with primary APS and no response to standard immunosuppressive therapy.
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood Adv |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6737408/ https://ncbi.nlm.nih.gov/pubmed/31506284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000465 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|